GlassScriptPhysician profile
Alisha A Perry
NPI 1215098835
$3,422.27
in general payments reported to CMS, 2019-2025
30 companies · $62.48 in 2025
The $62.48 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,184 · 2022: $857 · 2023: $878 · 2024: $441 · 2025: $62.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $579.29 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $517.65 | 2021-2024 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.85 | 2021-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $292.97 | 2021-2023 | |
| Astellas Pharma US INC | $263.93 | 2021-2024 | Myrbetriq, Veozah |
| Pfizer INC. | $223.85 | 2021-2024 | |
| Abbvie INC. | $186.09 | 2021-2024 | |
| Mylan Specialty L.P. | $130.72 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $94.94 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $92.02 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $89.89 | 2021-2024 | Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $76.64 | 2022-2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.78 | 2021-2024 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $65.78 | 2023-2024 | Gemtesa |
| Davol INC. | $65.24 | 2022-2025 | Arista |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $64.27 | 2022 | |
| Esperion Therapeutics, INC. | $50.85 | 2021-2022 | |
| Glaxosmithkline, LLC. | $35.92 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $32.33 | 2023-2024 | Camzyos, Eliquis |
| Antares Pharma, INC. | $27.72 | 2024 | Xyosted |
| Fidia Pharma USA INC. | $23.28 | 2024 | Hymovis |
| Phadia US INC. | $19.93 | 2023 | Immunocap |
| Pacira Pharmaceuticals Incorporated | $18.87 | 2025 | Exparel |
| Amarin Pharma, INC. | $18.69 | 2021 | |
| Solventum Corporation | $18.62 | 2025 | V.A.C.Ulta, V.A.C. Veraflo, Prevena |
| Radius Health, INC. | $16.65 | 2021 | |
| Orthofix Medical, INC. | $14.47 | 2024 | Physio-Stim |
| Exact Sciences Corporation | $13.10 | 2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $12.43 | 2022 | |
| Genentech USA, INC. | $4.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alisha Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.